JP2014532413A5 - - Google Patents

Download PDF

Info

Publication number
JP2014532413A5
JP2014532413A5 JP2014539033A JP2014539033A JP2014532413A5 JP 2014532413 A5 JP2014532413 A5 JP 2014532413A5 JP 2014539033 A JP2014539033 A JP 2014539033A JP 2014539033 A JP2014539033 A JP 2014539033A JP 2014532413 A5 JP2014532413 A5 JP 2014532413A5
Authority
JP
Japan
Prior art keywords
human
segment
animal
endogenous
segments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014539033A
Other languages
English (en)
Japanese (ja)
Other versions
JP6254528B2 (ja
JP2014532413A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/062065 external-priority patent/WO2013063361A1/en
Publication of JP2014532413A publication Critical patent/JP2014532413A/ja
Publication of JP2014532413A5 publication Critical patent/JP2014532413A5/ja
Application granted granted Critical
Publication of JP6254528B2 publication Critical patent/JP6254528B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014539033A 2011-10-28 2012-10-26 遺伝子改変t細胞受容体マウス Active JP6254528B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161552582P 2011-10-28 2011-10-28
US61/552,582 2011-10-28
US201261621198P 2012-04-06 2012-04-06
US61/621,198 2012-04-06
US201261700908P 2012-09-14 2012-09-14
US61/700,908 2012-09-14
PCT/US2012/062065 WO2013063361A1 (en) 2011-10-28 2012-10-26 Genetically modified t cell receptor mice

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017205098A Division JP6532924B2 (ja) 2011-10-28 2017-10-24 遺伝子改変t細胞受容体マウス

Publications (3)

Publication Number Publication Date
JP2014532413A JP2014532413A (ja) 2014-12-08
JP2014532413A5 true JP2014532413A5 (enExample) 2015-12-17
JP6254528B2 JP6254528B2 (ja) 2017-12-27

Family

ID=47178340

Family Applications (7)

Application Number Title Priority Date Filing Date
JP2014539033A Active JP6254528B2 (ja) 2011-10-28 2012-10-26 遺伝子改変t細胞受容体マウス
JP2017205098A Active JP6532924B2 (ja) 2011-10-28 2017-10-24 遺伝子改変t細胞受容体マウス
JP2018231026A Active JP6706311B2 (ja) 2011-10-28 2018-12-10 遺伝子改変t細胞受容体マウス
JP2020085787A Withdrawn JP2020146045A (ja) 2011-10-28 2020-05-15 遺伝子改変t細胞受容体マウス
JP2022075908A Active JP7305840B2 (ja) 2011-10-28 2022-05-02 遺伝子改変t細胞受容体マウス
JP2022208112A Active JP7656580B2 (ja) 2011-10-28 2022-12-26 遺伝子改変t細胞受容体マウス
JP2023214715A Withdrawn JP2024019646A (ja) 2011-10-28 2023-12-20 遺伝子改変t細胞受容体マウス

Family Applications After (6)

Application Number Title Priority Date Filing Date
JP2017205098A Active JP6532924B2 (ja) 2011-10-28 2017-10-24 遺伝子改変t細胞受容体マウス
JP2018231026A Active JP6706311B2 (ja) 2011-10-28 2018-12-10 遺伝子改変t細胞受容体マウス
JP2020085787A Withdrawn JP2020146045A (ja) 2011-10-28 2020-05-15 遺伝子改変t細胞受容体マウス
JP2022075908A Active JP7305840B2 (ja) 2011-10-28 2022-05-02 遺伝子改変t細胞受容体マウス
JP2022208112A Active JP7656580B2 (ja) 2011-10-28 2022-12-26 遺伝子改変t細胞受容体マウス
JP2023214715A Withdrawn JP2024019646A (ja) 2011-10-28 2023-12-20 遺伝子改変t細胞受容体マウス

Country Status (25)

Country Link
US (5) US9113616B2 (enExample)
EP (3) EP2771357B1 (enExample)
JP (7) JP6254528B2 (enExample)
KR (5) KR102148387B1 (enExample)
CN (5) CN107858333B (enExample)
AU (5) AU2012327204B2 (enExample)
BR (1) BR112014009203B1 (enExample)
CA (1) CA2853707A1 (enExample)
CY (2) CY1120945T1 (enExample)
DK (2) DK3424947T3 (enExample)
ES (2) ES2858978T3 (enExample)
HR (2) HRP20181626T1 (enExample)
HU (1) HUE053444T2 (enExample)
IL (4) IL305550B2 (enExample)
IN (1) IN2014CN03890A (enExample)
LT (2) LT2771357T (enExample)
MX (2) MX353134B (enExample)
PL (2) PL3424947T3 (enExample)
PT (2) PT2771357T (enExample)
RS (2) RS61455B1 (enExample)
RU (1) RU2661106C2 (enExample)
SG (2) SG11201401030WA (enExample)
SI (2) SI3424947T1 (enExample)
SM (2) SMT202100243T1 (enExample)
WO (1) WO2013063361A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61455B1 (sr) * 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
WO2013107413A1 (zh) * 2012-01-19 2013-07-25 中国科学院上海巴斯德研究所 磷酸化途径相关因子在调控调节性t细胞功能中的应用
ES2683071T3 (es) 2012-04-25 2018-09-24 Regeneron Pharmaceuticals, Inc. Direccionamiento mediado por nucleasas con grandes vectores de direccionamiento
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
MX388127B (es) 2013-12-11 2025-03-19 Regeneron Pharma Metodos y composiciones para la modificacion dirigida de un genoma.
DK3152312T3 (da) * 2014-06-06 2020-04-06 Regeneron Pharma Fremgangsmåder og sammensætninger til modifikation af et mållocus
WO2015196051A1 (en) * 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
DK3161128T3 (en) 2014-06-26 2018-11-05 Regeneron Pharma METHODS AND COMPOSITIONS FOR TARGETED GENTICAL MODIFICATIONS AND PROCEDURES FOR USE THEREOF
US20160081314A1 (en) * 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric Antigen Receptors
EP3221457B1 (en) 2014-11-21 2019-03-20 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
BR112017010793A2 (pt) * 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
MX388784B (es) 2014-12-19 2025-03-20 Regeneron Pharma Métodos y composiciones para la modificación genética dirigida a través de direccionamiento múltiple de una sola etapa.
MX2017012829A (es) * 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
WO2016177682A1 (en) 2015-05-06 2016-11-10 Snipr Technologies Limited Altering microbial populations & modifying microbiota
CN108366548B (zh) 2015-11-20 2021-10-08 瑞泽恩制药公司 具有人源化淋巴细胞活化基因3的非人动物
AU2017248259A1 (en) * 2016-04-07 2018-10-25 Bluebird Bio, Inc. Chimeric antigen receptor T cell compositions
IL308831A (en) 2016-04-08 2024-01-01 Immunocore Ltd T cell receptors
CN109640644B (zh) * 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
AU2018283319B2 (en) 2017-06-16 2023-11-09 Mayo Foundation For Medical Education And Research Materials and methods for increasing immune responses
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
CN112585276A (zh) * 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
WO2020022512A1 (ja) * 2018-07-26 2020-01-30 国立大学法人京都大学 外来抗原レセプター遺伝子導入細胞の製造方法
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
KR20220078607A (ko) * 2019-09-12 2022-06-10 티씨알2 테라퓨틱스 인크. 융합 단백질들을 이용한 tcr 재프로그래밍을 위한 조성물 및 방법들
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
WO2021195503A1 (en) * 2020-03-27 2021-09-30 2Seventy Bio, Inc. T cell receptors
CN113684258B (zh) * 2020-05-18 2024-08-20 上海赛比曼生物科技有限公司 用于检测鼠源tcr转基因拷贝数的试剂盒及方法
CN116981357A (zh) 2021-03-31 2023-10-31 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
CN120019068A (zh) * 2022-08-12 2025-05-16 独创目标实验室 具有人源化γ和δTCR可变基因的经遗传修饰的非人类
WO2024038165A1 (en) 2022-08-18 2024-02-22 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
CA3265746A1 (en) * 2022-09-22 2024-03-28 Regeneron Pharmaceuticals, Inc. GENETICALLY MODIFIED MICE EXPRESSING COMPONENTS OF A HUMAN CELLULAR IMMUNE SYSTEM
TW202520975A (zh) 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
GB2640828A (en) 2024-04-22 2025-11-12 T Therapeutics Ltd Methods and products for the generation and identification of T cells and TCRs
GB2642411A (en) 2024-04-22 2026-01-14 T Therapeutics Ltd T Cell Receptor identification and provision

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California TRANSGENIC ANIMALS HAVING TARGET LYMPHOCYTA TRANSDUCTION GENES.
US5523226A (en) 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
EP0910409A4 (en) 1996-03-05 2003-03-19 Scripps Research Inst RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS
US6320306B1 (en) * 1996-08-05 2001-11-20 Samsung Display Devices Co., Ltd. Shadow mask with porous insulating layer and heavy metal layer
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
WO2001027291A1 (en) 1999-10-12 2001-04-19 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7462486B2 (en) 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JPWO2002047474A1 (ja) 2000-12-13 2004-04-15 住友製薬株式会社 Hla−a24発現トランスジェニック動物及びその利用
DK1409646T3 (da) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
PT1421115E (pt) 2001-08-31 2005-07-29 Avidex Ltd Receptor de celulas t soluvel
JP4087338B2 (ja) 2001-11-15 2008-05-21 キリンファーマ株式会社 キメラ非ヒト動物
WO2003068819A1 (en) 2001-12-22 2003-08-21 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
DE60106469T2 (de) 2001-12-22 2005-10-13 4-Antbody AG Verfahren zur Herstellung von genetisch veränderten Lymphozyten Vorläuferzellen von Wirbeltieren und deren Gebrauch zur Produktion von heterologen Bindeproteinen
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
AU2003271904B2 (en) 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
WO2004042004A2 (en) * 2002-10-30 2004-05-21 The Wistar Institute Of Anatomy And Biology Mouse model for autoimmune disorders
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
US20090304657A1 (en) 2006-05-03 2009-12-10 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Chimeric t cell receptors and related materials and methods of use
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
WO2008051854A2 (en) 2006-10-20 2008-05-02 Trustees Of Boston University A tunable genetic switch for regulating gene expression
JP2008159109A (ja) 2006-12-21 2008-07-10 Matsushita Electric Ind Co Ltd データ転送装置
EP2262898B1 (en) 2008-03-07 2018-01-24 Regeneron Pharmaceuticals, Inc. Es cell-derived mice from diploid host embryo injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
WO2010107400A1 (en) * 2009-03-20 2010-09-23 Agency For Science, Technology And Research Genetically modified animal and method of obtaining the same
DK3241435T3 (da) * 2009-07-08 2021-08-23 Kymab Ltd Dyremodeller og terapeutiske molekyler
RU2425880C2 (ru) 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
PL3248462T3 (pl) 2010-03-31 2024-07-08 Ablexis, Llc Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
CN103025884B (zh) 2010-07-26 2015-11-25 特里安尼公司 转基因动物和使用方法
WO2012039779A1 (en) 2010-09-24 2012-03-29 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
CN105950654B (zh) 2010-11-27 2020-03-20 朱坚 一种人源化的转基因动物
RS61455B1 (sr) * 2011-10-28 2021-03-31 Regeneron Pharma Genetski modifikovani miševi t ćelijskog receptora
MX2017012829A (es) 2015-04-06 2018-02-23 Regeneron Pharma Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses

Similar Documents

Publication Publication Date Title
JP7386292B2 (ja) 操作されたイムノグロブリンラムダ軽鎖座位を有する非ヒト動物
RU2014121160A (ru) Генетически модифицированные в отношении т-клеточного рецептора мыши
US12356967B2 (en) Immunoglobulin lambda light chain and uses thereof
EP3609319B1 (en) Mouse models and therapeutic molecules
EP3871497B1 (en) Rodent models and therapeutic molecules
JP2017513520A5 (enExample)
CN108467873B (zh) 一种cd132基因缺失的免疫缺陷动物模型的制备方法及应用
WO2011158009A1 (en) Animal models and therapeutic molecules
EP3864038A1 (en) Animal models and therapeutic molecules
Eguren-Santamaria et al. Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic
CN109136275A (zh) 人源化gitr基因改造动物模型的制备方法及应用
TW202520975A (zh) 基因改造之囓齒動物及囓齒動物細胞以及其等用途
KR20250116681A (ko) 공통 경쇄를 발현하는 설치류
HK40058708B (en) Rodent models and therapeutic molecules
HK40060958B (en) Rodent models and therapeutic molecules
HK40060958A (en) Animal models and therapeutic molecules
HK40014986B (en) Animal models and therapeutic molecules
HK40075382B (en) Rodent models and therapeutic antibodies
Narayan The Function of Innate γδ T Cell Subsets is Molecularly Programmed in the Thymus in Three Stages: A Dissertation
HK1180535B (en) Animal models and therapeutic molecules